Related Experiment Video
Updated: Jun 25, 2026
Production of High-Titer Recombinant Newcastle Disease Virus from Allantoic Fluid
Published on: May 25, 2022
Genetically engineered Newcastle disease virus for malignant melanoma therapy
1Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA. dmitriy.zamarin@mssm.edu
Abstract:
Despite the advances in cancer therapies in the past century, malignant melanoma continues to present a significant clinical challenge due to lack of chemotherapeutic response. Systemic therapy with immunostimulatory agents such as interferon and interleukin-2 (IL-2) has shown some promise, though each is associated with significant side effects. Over the past 50 years, oncolytic Newcastle disease virus (NDV) has emerged as an alternative candidate for cancer therapy. The establishment of reverse-genetics systems for the virus has allowed us to further manipulate the virus to enhance its oncolytic activity. Introduction of immunomodulatory molecules, especially IL-2, into the NDV genome was shown to enhance the oncolytic potential of the virus in a murine syngeneic colon carcinoma model. We hypothesize that a recombinant NDV expressing IL-2 would be an effective agent for therapy of malignant melanoma. We show that recombinant NDV possesses a strong cytolytic activity against multiple melanoma cell lines, and is effective in clearing established syngeneic melanoma tumors in mice. Moreover, introduction of murine IL-2 into NDV significantly enhanced its activity against syngeneic melanomas, resulting in increased overall animal survival and generation of antitumor immunity. These findings warrant further investigations of IL-2-expressing NDV as an antimelanoma agent in humans.
Insights
A novel oncolytic Newcastle disease virus (NDV) engineered to express interleukin-2 (IL-2) demonstrates potent anti-melanoma activity. This enhanced NDV effectively clears tumors and improves survival in preclinical models, offering a promising new cancer therapy.
Area of Science:
- Oncology
- Virology
- Immunotherapy
Background:
- Malignant melanoma remains a therapeutic challenge due to poor response to conventional chemotherapy.
- Current systemic therapies like interferon and interleukin-2 (IL-2) have limitations including significant side effects.
- Oncolytic viruses, specifically Newcastle disease virus (NDV), are being explored as alternative cancer treatments.
Purpose of the Study:
- To investigate the efficacy of a recombinant NDV engineered to express IL-2 for malignant melanoma therapy.
- To evaluate the oncolytic potential and immunomodulatory effects of IL-2-expressing NDV against melanoma.
Main Methods:
- Development of a recombinant NDV expressing murine IL-2.
- Assessment of cytolytic activity against various melanoma cell lines in vitro.
- Evaluation of therapeutic efficacy in a syngeneic murine melanoma model, including tumor clearance and survival analysis.
Main Results:
- Recombinant NDV exhibited significant cytolytic effects on multiple melanoma cell lines.
- IL-2-expressing NDV demonstrated effectiveness in clearing established syngeneic melanoma tumors in mice.
- Enhanced viral therapy led to improved animal survival and induced antitumor immunity.
Conclusions:
- Recombinant IL-2-expressing NDV is a potent agent against malignant melanoma in preclinical studies.
- The enhanced oncolytic and immunomodulatory properties warrant further investigation for human melanoma treatment.
